Olema Pharmaceuticals (OLMA) Cash from Financing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash from Financing Activities data on file, last reported at $45.7 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 20487.39% year-over-year to $45.7 million in Q1 2026; TTM through Mar 2026 was $256.8 million, a 1.32% decrease from a year earlier, with the FY2025 full-year figure at $211.3 million, down 21.4% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $45.7 million, down from $213.6 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for OLMA reached as high as $244.3 million in Q4 2024 and fell as low as -$2.5 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $38.8 million across 5 years, with a median of $273000.0 in 2022.
• Across the five-year window, Cash from Financing Activities surged 123134.91% in 2023 and tumbled 116.14% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $273000.0 in 2022, then soared by 91.58% to $523000.0 in 2023, then surged by 46611.28% to $244.3 million in 2024, then dropped by 12.59% to $213.6 million in 2025, then sank by 78.6% to $45.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $45.7 million in Q1 2026, $213.6 million in Q4 2025, and $41000.0 in Q3 2025.